Replies to post #336012 on Bioelectronics Corp (BIEL)

[3331]

The catalysts and projections have been provided on numerous occasions, just go back and look.

Since your expertise is insurance, would you mind if I asked you some questions about my policies?

[3331]

I previously provided you the numbers you requested using the VA and 1,000 veterinary offices as catalysts. Here are some additional numbers using Taiwan as a catalyst, using beacham's conservative numbers of 1% market penetration w/$10 profit/unit yields $43 million revenue:

$3 million = break even, cash flow positive: pps = .01.
Each additional $2.5 million/year should result in an additional .01 increase in pps (P/E = 100).

For revenue = $43 million, profit = $40 million (and applying the tax loss carryforward), resulting pps =
.17 (P/E = 100)
.33 (P/E = 200)
.49 (P/E = 300)

However, there are several factors that indicate this estimate might be extremely conservative, such as:
1) Taiwan appears to be using the RecoveryRx (requires doctor approval) version of Actipatch (OTC), which would have a higher profit than $10/unit.
2) market penetration will likely be higher than 1%.

Therefore, a case could be made for increasing the above estimates 10-fold or more (although tax would then need to be factored in). Now factor in the VA, veterinary, and other rumored contracts (if they materialize), and you're taking some serious money!

NOW, SINCE I ANSWERED YOUR QUESTIONS, CAN YOU ANSWER MY INSURANCE POLICY QUESTIONS?